Thoracic Cancer · Published 2026-07-29 · DOI 10.1111/1759-7714.70313
Marion Caumeil, Julie A. Vendrell, Simon Cabello‐Aguilar, Sarah Cavaillon, Quentin Dominique Thomas, Jérôme Solassol
ABSTRACT Circulating tumor DNA (ctDNA) monitoring may detect resistance to KRASG12C inhibitors earlier than conventional imaging. However, in the specific context of KRASG12C inhibitors, the temporal relationship between molecular, radiologic, and clinical progression remains poorly characterized. A 66‐year‐old woman with KRASG12C/STK11/KEAP1‐mutant lung adenocarcinoma received second‐line adagrasib after progression on chemo‐immunotherapy. Serial ctDNA monitoring by droplet digital PCR and targeted next‐generation sequencing was performed. Baseline KRASG12C ctDNA (6205.3 copies/mL) declined to 3.2 copies/mL after 7 weeks, indicating initial response. However, ctDNA levels rose to 21.1 copies/mL at month 4 and 315.2 copies/mL at month 6. Concurrent NGS revealed three emergent KRAS mutations (G12D, G13D, Q61H), confirming polyclonal resistance. Notably, CT and MRI imaging remained stable by RECIST criteria throughout this period. Significant clinical deterioration, requiring prolonged hospitalization, occurred approximately 8 weeks after initial ctDNA rise. The patient died 2 months after detection of resistance mutations. In this case, NGS ctDNA detected three acquired KRAS resistance mutations in addition to the original G12C, during a prolonged period of radiographic stability, illustrating polyclonal evolution under adagrasib pressure. These findings suggest that longitudinal liquid biopsy monitoring may provide early detection of resistance in KRASG12C‐mutant NSCLC.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Caumeil, M., Vendrell, J., Cabello‐Aguilar, S., et al. (2026). ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib‐Treated NSCLC. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70313